Transcutaneous pO₂ Monitoring in PICU (NCT07478380) | Clinical Trial Compass
RecruitingNot Applicable
Transcutaneous pO₂ Monitoring in PICU
Turkey (Türkiye)50 participantsStarted 2026-03-10
Plain-language summary
Arterial blood gas analysis is commonly used in pediatric intensive care units (PICUs) to assess oxygen and carbon dioxide levels in critically ill children. However, arterial blood sampling is invasive, can be painful, and may need to be repeated frequently. Transcutaneous monitoring provides a noninvasive method to continuously measure oxygen (pO₂) and carbon dioxide (pCO₂) levels through the skin, but its accuracy in critically ill pediatric patients requires further evaluation.
The purpose of this observational study is to compare transcutaneous pO₂ and pCO₂ measurements with arterial blood gas values in pediatric intensive care unit patients. By analyzing paired measurements obtained simultaneously during routine clinical care, this study aims to evaluate the agreement between transcutaneous and arterial measurements, with a particular focus on whether transcutaneous pO₂ can serve as a reliable alternative to arterial sampling.
The results of this study may help clarify the role of transcutaneous monitoring in pediatric intensive care and may contribute to reducing the need for invasive blood sampling in selected patients.
Who can participate
Age range
1 Month – 18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Eligibility Criteria
Inclusion Criteria:
* Age between 1 month and 18 years
* Admission to the Pediatric Intensive Care Unit (PICU)
* Presence of an arterial catheter allowing arterial blood gas (ABG) sampling
* Simultaneous or paired transcutaneous pCO₂ and pO₂ monitoring available
* Hemodynamically stable at the time of measurement
Exclusion Criteria:
* Severe skin disease, burns, or local skin infection at the transcutaneous sensor site
* Severe peripheral perfusion impairment (e.g., refractory shock or high-dose vasopressor support)
* Congenital or acquired conditions interfering with accurate transcutaneous measurements
* Technical failure or inability to obtain reliable transcutaneous readings
* Missing or incomplete paired ABG-transcutaneous measurement data
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Agreement Between Transcutaneous pO₂ and Arterial pO₂
Timeframe: At the time of each paired transcutaneous monitoring and arterial blood gas measurement during PICU admission (up to 28 days)